High-caloric nutritive supplement

FIELD: food industry.

SUBSTANCE: invention relates to a nutritive supplement, to a method of its production and application. The nutritive supplement, according to the invention, contains a protein source including milk protein isolate and/or canola protein, a fat source, a carbohydrate source and water and has calorific value 2.25 - 3.25 cal/ml and viscosity lower than 120 centiPoise. The method for production of the supplement envisages a mixture preparation of water and the protein source, the fat source, the carbohydrate source, the mixture treatment with direct injection of vapour, the mixture homogenisation. The nutritive supplement, according to the invention, is applied in combination with one or more medicaments during therapy of nutritional deficiency. The nutritive supplement has high calorific value and will be useful for persons suffering from body weight loss.

EFFECT: milk protein isolate treatment with application of direct injection of vapour allows to reduce viscosity of the nutritive supplement.

20 cl, 4 tbl, 12 ex

 

The technical field to which the invention relates.

In a General sense, the invention relates to nutritional supplements, and more specifically high-calorie nutritional supplements containing milk protein isolate and/or canola protein as the primary or sole source of protein. The invention also concerns methods of production and reception of such nutritional supplements.

The level of technology

Any individual gets calories from three main sources - proteins, fats and carbohydrates. Finding the right balance between these sources of calories in the diet of an individual depends on a number of factors, including, for example, the age of the individual, the level of physical activity and the disease, disorder or condition, which may suffer the individual. For example, individuals older usually requires a smaller total number of calories and fewer calories from fat than younger individuals.

Nutritional supplements have been developed to increase the total number of calories consumed and/or changes in the ratio between proteins, fats and carbohydrates in the diet of the individual. Patients individuals may experience a loss of appetite, so they will be useful nutritional Supplement with a high content of calories, is able to provide enough total calories in about the found volume.

In particular, individuals suffering from weight loss, can only benefit from intake of high-calorie nutritional supplements. Examples of diseases, disorders and conditions that are accompanied by weight loss or cause weight loss, are, for example, anorexia nervosa, disease causing exhaustion, including cancer, acquired immunodeficiency syndrome (AIDS) and sarcopenia (age related loss of muscle mass); chronic disease; functional disorders, including mental disorders and physical infirmity; deterioration of mental faculties and wounds.

Most cases of unintentional weight loss include loss of muscle mass. In such cases, nutritional supplements, containing a larger proportion of proteins and/or amino acids, can be particularly useful, as they provide material for the formation of new muscle tissue. However, the increase in both total calories and protein in the nutritional Supplement may lead to an increase in viscosity of the additive. This can become particularly problematic in the case of additives, accept oral or enteral route. In addition, supplementation with high protein content may have an unacceptable taste, which creates an additional problem for orally taken supplements.

Milk protein provides a high concentration of swaimeh amino acids and is therefore ideal for inclusion as a protein source in nutritional supplements. More specifically, the protein of milk supplies as slowly absorbed (casein)and rapidly absorbed (whey protein) proteins. This protein component as slow absorbing casein contributes to the deposition of protein after each meal due to the inhibition of protein breakdown without an excessive increase in the concentrations of amino acids. Quickly absorbed protein component (whey protein) stimulates protein synthesis. Therefore, the regulation of the ratio between casein and whey proteins allows you to control the protein content taking into account the needs of each individual. For example, the inclusion of a nutritional Supplement increased amount of whey protein will promote the formation of muscle tissue, which is especially preferable for individuals suffering from loss of muscle tissue.

As explained above, increased protein content can lead to an increase in the viscosity of nutritional supplements. This fully applies to milk protein, soy protein and Caseinates. Attempts to adequately reduce the viscosity of the additive by conducting heat treatment in the boiler with the corresponding exposure time, high-temperature short-time (WTCV) processing and sterilization, for example, using direct injection of steam (PIP) or UltraISO temperaturey (SWT) processing in an autoclave or completely failed, or lead to undesirable results, in particular, to the burning of proteins with high viscosity to unacceptable taste, such as powdery consistency, primarily taste, separation into phases and swelling. Therefore, high-protein nutritional supplements were used as a source of protein to other proteins, but not milk protein, such as soy protein and Caseinates, and limit the amount of calories in these supplements. However, the use of these proteins as a source of protein has significant drawbacks. For example, compared with milk protein soy protein has a deficiency of methionine, lysine and branched chain amino acids (leucine, isoleucine and valine). In addition, the presence of soy protein inhibitors of trypsin affects its digestibility and hence its bioavailability. As a consequence, the soy protein is generally regarded as the source of protein is of lower quality than milk protein.

Proteins canola was used in feed for cattle, not for food purposes, and therefore there is no history of consumption for human nutrition. Canola was formerly known as rape seed. Rape seed is rich in erucic acid, a toxin for mammals mono-gastric. Was derived from a plant that contains erucic acid, which has led the largest annual planting canola (the word comes from the expression of Canadian oil (canadian oil)). Because the history of consumption for food purposes was not, the balance of plant materials after production of canola oil was used for animal feed. More recently, companies have been able to establish excellent quality amino acid profile of proteins canola seeds.

Thus, there is a need for high-calorie nutritional Supplement, containing a source of high quality protein, which has no shortage of the above amino acids.

Disclosure of inventions

The invention provides a nutritional Supplement containing a source of protein, including milk protein isolate and/or canola proteins, as well as corresponding methods of its production and use in the treatment of deficiencies in the individual.

In the first aspect of the invention provides a nutritional Supplement containing a source of protein, including milk protein isolate and/or canola proteins; source of fat and a source of carbon, and having a caloric content of about from 2.25 to 3.25 calories/ml and a viscosity below about 120 centipoise (CP).

In the second aspect of the invention provides a method of manufacturing a liquid nutritional Supplement, providing for the preparation of a mixture of water and source of protein, including milk protein isolate and/or canola proteins; exposure of the mixture to the processing of direct steam injection (PIP) and homogenization of the mixture is, in which liquid nutrient additive has a viscosity below about 120 SP.

In the third aspect of the invention provides a method of treatment of a nutrient deficit in the individual, providing for the admission of the individual a nutritional Supplement that contains a source of protein, including milk protein isolate and/or canola proteins; source of fat and a source of carbohydrate, in which the nutritional Supplement has a caloric content of about from 2.25 to 3.25 cal/ml and a viscosity below about 100 CP.

Disclosed above aspects of the present invention help to solve the above and others not discussed here, the problems faced by a qualified technician.

Brief description of figures

These and other distinguishing features of the present invention will become apparent from the following detailed description of various aspects of the invention together with the attached drawing, which reflect different ways of practical embodiment of the invention, in particular, in the drawing schematically shows an illustrative example of the method according to the invention.

It should be noted that the drawing is made not to scale and is for illustration only typical aspects of the invention and therefore should not be considered as limiting the scope of the invention.

Detailed description of the invention

As mentioned above, sabreena provides high-calorie nutritional Supplement, contains milk protein isolate and/or canola protein as the primary or sole source of protein. The invention also provides methods of producing and receiving specified nutritional supplements.

In the context of the description, the terms "treatment" and "treat" refer to both prophylactic or preventive treatment, or radical, or alter the course of disease treatment, including treatment of patients with an increased risk of developing the disease or suspected occurrence of the disease, and patients who are already ill or diagnosed with a disease or disease state. The terms "treatment" and "treat" also include support and/or improve the health of the individual, not suffering from any disease, but which may be susceptible to the development of unhealthy state, such as the imbalance of nitrogen, the loss of muscle mass or weight loss.

Consequently, the "effective amount" means the amount that cures disease or disease state of an individual or in a more General sense, provides nutritional, physiological or therapeutic support of the individual. In addition, although the terms "individual" and "patient" are often used in the description as referring to the person, the invention is not limited to man. Therefore, the terms "individual" and "patient" respectively against the be any mammal, suffering from a painful condition, or who are at risk of developing painful conditions, such as weight loss.

Processing of milk protein isolate and/or canola protein direct steam injection

Unexpectedly, it was found that the processing of milk protein isolate and/or canola protein using direct injection of steam (PIP) reduces the viscosity of the protein to a level that makes it suitable this protein for use in the nutritional Supplement, in particular, to accept oral nutritional Supplement. PIP is used in the food industry since the early 1930-ies. The principle of this treatment is well known to the skilled in the art specialist and not described in detail here.

Returning to the drawing, it is necessary to say that it presents the diagram of a method of production of liquid nutritional supplements one of the options practical embodiment of the invention. At the initial stage S1 is mixing the protein slurry containing water and a source of protein, including milk protein isolate and/or canola protein. In most cases, before mixing with the protein source water is heated to a temperature of from about 48,9°C to 87.8°C, preferably from about 51,7°C to 79.4°C, more preferably from about 54,4°C to 65.6°C and most preferably from about 57,2°C to 62.8°Smelkova suspension may also contain any number of traditionally used ingredients including, for example, defoamers, citrate(s), source of fat, a source of carbohydrates, emulsifiers, vitamins, minerals and flavour. Preferably the protein suspension stage S1 includes at least hot water and a source of protein, including milk protein isolate. If you want to use a defoamer, it is preferably introduced into the protein suspension at the stage S1.

In optional stage S2 in the protein slurry is added to the traditionally used ingredients that were not added to the protein suspension at the stage S1, or additional ingredients are added at the stage S1, and the resulting total mixture was stirred. As noted above, such ingredients may include, for example, citrate(s), source of fat, a source of carbohydrates, emulsifiers, vitamins, minerals and flavour. If the mixture of ingredients you want to add one or more citrates, they are preferably added at stages S1 or S2.

At stage S3, the mixture of ingredients stage S1 and optional stage S2 is processed by the direct injection of steam (PIP). Preferably stage of PIP according to the present invention includes heating a mixture of ingredients to a temperature of about 121, 1million°C for about 45 seconds, followed an instant cooling in the vacuum chamber is about to 71.1°C.

On n the mandatory stage S4 to the mixture of ingredients added ingredients, which were not added at stages S1 or S2 or additional ingredients are added at the indicated stages. As noted above, such ingredients may include, for example, a source of fat, a source of carbohydrates, emulsifiers, vitamins, minerals and flavour. If you want to add a source of fat, a source of carbohydrate or emulsifying agents, they are preferably added at stages S1, S2 or S4.

On stage S5, the homogenized mixture of ingredients. Can be used with any method of homogenization. However, the preferred method of homogenization of the present invention is a two-stage homogenization at a pressure of approximately 175,8 kg/cm2and 35 kg/cm2. Optional stage S5 may include more than one homogenizing a mixture of ingredients.

In optional stage S6 to the mixture of ingredients added ingredients that were not added at stages S1, S2, or S4, or additional ingredients are added at the indicated stages. As noted above, such ingredients may include, for example, vitamins, minerals and flavour.

In optional stage S7, the blend of ingredients is again homogenized. The method of homogenization and/or parameters are optional stage S7 may be the same as at stage S5, or differ from the parameters n the stage S5. If the stage S7 is carried out, it includes cooling the mixture of ingredients to a temperature below about 7.2°C, followed by homogenization. If optional step S7 is not performed, the mixture of ingredients may be cooled to a temperature below about 7.2°C, and then gomogeniziruetsya on stage S5 or after adding additional ingredients to optional stage S6. In any case, the mixture of ingredients may not necessarily be supported for approximately 36 hours at a temperature below about 7.2°C.

In conclusion, the mixture of ingredients is exposed or aseptic process at the stage S8 or the process of autoclaving on stage S9. Aseptic process stage S8 may include, for example, ultra-high-temperature (SWT) processing or PIP-processing at temperatures above about 137,8°C With subsequent sterile homogenization. Then is aseptic bottling the finished additive packages Tetra-Brik, cans, bottles or other suitable container known from the prior art.

The process of autoclaving stage S9 may include, for example, the bottling of the finished additive in cans, bottles or other suitable container known from the prior art, and subsequent sterilization in the autoclave.

Supplements manufactured by a process shown in the drawing, have no more the kind of viscosity, than the well-known supplements containing milk protein isolate. In most cases supplements are made according to the invention have a viscosity below about 120 JV, preferably below about 100 SP, more preferably from about 50 SP 90 SP, most preferably from about 50 SP 75 SP. In addition, PIP-processing protein isolate milk protein or other protein sources at an early stage of the production process contributes to a significant reduction in the viscosity of the mixture of ingredients in the continuation of the remaining stages of the production process. In some cases, the viscosity, having place before the beginning of the production process, can be reduced by 500-1000 CPS (at 10°C. This gives a great advantage when large-scale production of the additive, as it facilitates the transportation of the additive from one stage of production to another, for example, pumping the additive pump from the tank for exposure to the place of final homogenization or sterilization.

The following examples serve only to illustrate the invention and in no way limit the methods of production of the additive according to the invention.

Example 1

To heat water to 60°C-81,2°C. Add protein and antifoam; stir.

Add citrate(s) and stir.

To sterilize the direct injection of steam (PIP) at 121, 1million°C for 45 sec and novenna to cool in the vacuum chamber to ~71,1°C.

Add carbohydrates and fats/emulsifiers; stir.

Add vitamins, minerals and flavoring additives; stir.

Homogenize at 175,8/35 kg/cm2.

Cooling to <7,2°C.

The product can be stored within 0-36 hours <7,2°C.

The UVT (ultra-high-temperature - or PIP-processing >137,8°C and sterile homogenization.

Aseptic filling packages Tetra-Brik, cans or bottles.

Example 2

To heat water to 60°C-81,2°C. Add protein and antifoam; stir.

PIP at 121, 1million°C for 45 seconds and immediately cooled in the vacuum chamber to ~71,1°C.

Add carbohydrates and fats/emulsifiers; stir.

Add vitamins, minerals and flavoring additives; stir.

Homogenize at 175,8/35 kg/cm2.

Cooling to <7,2°C.

The product can be stored within 0-36 hours <7,2°C.

The TVC - or PIP-processing >137,8°C and sterile homogenization.

Aseptic filling packages Tetra-Brik, cans or bottles.

Example 3

To heat water to 60°C-81,2°C. Add protein, fat, emulsifiers and antifoam; stir.

PIP at 121, 1million°C for 45 seconds and immediately cooled in the vacuum chamber to ~71,1°C.

Homogenize at 175,8/35 kg/cm2.

Add carbohydrates; stir.

Add vitamins, minerals and flavoring add and; mix.

Homogenize at 175,8/35 kg/cm2.

Cooling to <7,2°C.

The product can be stored within 0-36 hours <7,2°C.

The TVC - or PIP-processing >137,8°C and subsequent homogenization.

Aseptic filling packages Tetra-Brik, cans or bottles.

Example 4

To heat water to 60°C-81,2°C. Add protein, fat, carbohydrate, emulsifying agents and antifoam; stir.

PIP at 121, 1million°C for 45 seconds and immediately cooled in the vacuum chamber to ~71,1°C.

Homogenize at 175,8/35 kg/cm2.

Add vitamins, minerals and flavoring additives; stir.

Cooling to <7,2°C.

The product can be stored within 0-36 hours <7,2°C.

The TVC - or PIP-processing >137,8°C and subsequent homogenization.

Aseptic filling packages Tetra-Brik, cans or bottles.

Example 5

To heat water to 60°C-81,2°C. Add protein, carbohydrate and antifoam; stir.

PIP at 121, 1million°C for 45 seconds and immediately cooled in the vacuum chamber to ~71,1°C.

Add the fat and emulsifiers.

Homogenize at 175,8/35 kg/cm2.

Add vitamins, minerals and flavoring additives; stir.

Cooling to <7,2°C.

The product can be stored within 0-36 hours <7,2°C.

The TVC - or PIP-processing >137,8°C and subsequent homogenization.

Aseptic is oslib in packages Tetra-Brik, cans or bottles.

Example 6

To heat water to 60°C-81,2°C. Add protein, carbohydrate, fat, emulsifiers, minerals, some vitamins and antifoam; stir.

PIP at 121, 1million°C for 45 seconds and immediately cooled in the vacuum chamber to ~71,1°C.

Homogenize at 175,8/35 kg/cm2.

Add vitamins and flavor additives; stir.

Cooling to <7,2°C.

The product can be stored within 0-36 hours <7,2°C.

The TVC - or PIP-processing >137,8°C and subsequent homogenization.

Aseptic filling packages Tetra-Brik, cans or bottles.

Example 7

To heat water to 60°C-81,2°C. Add protein and antifoam; stir.

Add citrate(s) and stir.

PIP at 121, 1million°C for 45 seconds and immediately cooled in the vacuum chamber to ~71,1°C.

Add carbohydrates and fats/emulsifiers; stir.

Add vitamins, minerals and flavoring additives; stir.

Homogenized in two stages at 175,8/35 kg/cm2.

Cooling to <7,2°C.

The product can be stored within 0-36 hours <7,2°C.

Filling in cans or bottles and sterilized in an autoclave.

Example 8

To heat water to 60°C-81,2°C. Add protein and antifoam; stir.

PIP at 121, 1million°C for 45 seconds and immediately cooled in the vacuum chamber to ~71,1°C.

Add carbohydrate and fat/emulsifier; mix.

Add vitamins, minerals and flavoring additives; stir.

Homogenized in two stages at 175,8/35 kg/cm2.

Cooling to <7,2°C.

The product can be stored within 0-36 hours <7,2°C.

Filling in cans or bottles and sterilized in an autoclave.

Example 9

To heat water to 60°C-81,2°C. Add protein, fat, emulsifier, and antifoam; stir.

PIP at 121, 1million°C for 45 seconds and immediately cooled in the vacuum chamber to ~71,1°C.

Homogenize at 175,8/35 kg/cm2.

Add carbohydrates; stir.

Add vitamins, minerals and flavoring additives; stir.

Homogenize at 175,8/35 kg/cm2.

Cooling to <7,2°C.

The product can be stored within 0-36 hours <7,2°C.

Filling in cans or bottles and sterilized in an autoclave.

Example 10

To heat water to 60°C-81,2°C. Add protein, fat, carbohydrate, emulsifying agents and antifoam; stir.

PIP at 121, 1million°C for 45 seconds and immediately cooled in the vacuum chamber to ~71,1°C.

Homogenize at 175,8/35 kg/cm2.

Add carbohydrates; stir.

Add vitamins, minerals and flavoring additives; stir.

Homogenize at 175,8/35 kg/cm2.

Cooling to <7,2°C.

The product can be stored within 0-36 hours <7,2°C.

Ro is Liv in cans or bottles and sterilized in an autoclave.

Example 11

To heat water to 60°C-81,2°C. Add protein, carbohydrate and antifoam; stir.

PIP at 121, 1million°C for 45 seconds and immediately cooled in the vacuum chamber to ~71,1°C.

Add the fat and emulsifiers.

Homogenized in two stages at 175,8/35 kg/cm2.

Add vitamins, minerals and flavoring additives; stir.

Cooling to <7,2°C.

The product can be stored within 0-36 hours <7,2°C.

Filling in cans or bottles and sterilized in an autoclave.

Example 12

To heat water to 60°C-81,2°C. Add protein, carbohydrate, fat, emulsifiers, minerals, some vitamins and antifoam; stir.

PIP at 121, 1million°C for 45 seconds and immediately cooled in the vacuum chamber to ~71,1°C.

Homogenized in two stages at 175,8/35 kg/cm2.

Add vitamins and flavor additives; stir.

Cooling to <7,2°C.

The product can be stored within 0-36 hours <7,2°C.

Filling in cans or bottles and sterilized in an autoclave.

High-calorie nutritional Supplement

The invention also applies to dietary supplements containing source of protein, including milk protein isolate and/or canola protein and having a viscosity that allows you to take these supplements orally. Nutritional supplements according to the invention can be made in the above way is or in any other way.

Nutritional supplements according to the invention is in most cases characterized by a high density of calories - about from 2.25 to 3.25 cal/ml protein Source provides from about 10% to 22% of the total number of calories in addition, the source of fat is from about 34% to 55%, and a source of carbohydrates - from about 25% to 55% of total calories in addition.

Table. 1 shows a typical limits for the number of ingredients in nutritional supplements according to the invention.

The nutritional supplements of the invention contain milk protein isolate and/or canola protein as the primary or sole source of protein. As noted above, when the additive manufacturing method according to the invention PIP-processing reduces the viscosity of the additive that allows the use of milk protein isolate as the protein source and to compensate, thus, the lack of amino acids in feed additives known from the prior art. Nutritional supplements according to the invention can also be included as a protein source, one or more of the total milk protein, milk protein concentrate, soy protein isolate, hydrolyzed whey protein and free amino acids. The protein source may include canola proteins, such as Supertein (fraction of 2S canola protein and Puratein (fraction of 12S canola protein) from ADM. And the source of protein may include branched chain amino acids (ACRC) (i.e. leucine, isoleucine and/or valine) in any form, for example in the form of free amino acids; native proteins in the form of dipeptides, tripeptides, fractionated protein or hydrolyzed protein; in enriched form (isolate protein) and/or in salt form. Similarly, ACRC can be entered in any combination of the above. With the introduction of ACRC in the nutritional Supplement according to the invention the number is preferably at least about 5% to 50% by weight of a source of amino nitrogen (i.e.% of the total number of amino acids and, therefore, % of total calories through protein source), more preferably at least about 10% to 40% of this mass, even more preferably at least about 15% to 35% of the specified weight and most preferably at least from about 22% to 35% of this weight.

In addition, a nutritional Supplement according to the invention can also contain a source of fat (for example, one or more of canola oil, corn oil, cottonseed oil, soybean oil, soy lecithin, high oleic sunflower oil, sunflower oil, fish oil, medium chain triglycerides (medium chain triglycerides (MCT), high oleic safflower oil, safflower oil, olive oil, borage oil (borrajo), black currant oil, evening primrose oil, Flaxseed oil, pall is oakboro oil and coconut oil). Preferably can be used cod-liver oil, for example, concentrated fish oil containing about 70% eicosapentaenoic acid (EPA), or oil containing about 45% EPA and about 10% docosahexaenoic acid (DHA). This oil may include these fatty acids in the form of manufactured finished products brand ERAH® 4510 from Pronova biocare. In one variant embodiment, the composition according to the invention includes from about 2.5 g to 7.5 g of fish oil per serving, more preferably from about 3.5 g to 6.5 g, even more preferably from about 4.5 g 5.5 g, and most preferably about 5.5, Such a composition may alternatively or also include from about 0.5 g to 5 g of medium chain triglycerides (MCT/portion, preferably from about 1 g to 4.5 g, more preferably from about 1.5 g to 4 g, even more preferably from about 2 g to 3.5 g, most preferably from about 2.5 g to 3 g In typical cases in a day can take from two to three servings of compositions according to the invention, although they may be receiving and five to six servings.

Many of the sources of fat listed above include n-3 polyunsaturated (omega-3) fatty acids such as alpha linolenic acid (ALA), EPA and DHA, either individually or in combination. In one variant embodiment, the composition according to the invention contains fish oil, providing the th from about 0.5 g to 3.0 g of n-3 polyunsaturated fatty acids, preferably from about 1.5 g to 2.0 g of n-3 polyunsaturated fatty acids.

If there is only one EPA, its quantity may be, for example, at least about 600 mg to 2 g/portion, preferably at least from about 1.5 g to 1.8 g/serving of the composition. EPA and DHA may be present, for example, in a combination in which EPA is present in an amount from about 500 mg to 1.5 g, preferably about 1.0 g/portion of the composition, and DHA is present in amount from about 250 mg to 1.5 g, preferably from about 500 mg to 750 mg, more preferably about 650 mg per serving of the composition. In one variant embodiment, the composition according to the invention contains both EPA and DHA in the approximate ratio of 2:1, 1:2 or 1.5:1.

In another variant embodiment, the composition according to the invention can include a mixture of n-6 polyunsaturated fatty acids such as linoleic acid and one or more n-3 polyunsaturated fatty acids, such as ALA, EPA and DHA. These n-6 and n-3 polyunsaturated acids can be present in an approximate ratio of 0.1:1.0 and 1.0 to:0,1 (for example, 0,2:1,0; 0,5:1,0; 0,8:1,0; 1:1; 1,2:1,0 and 1.5:1,0, more preferably about 1.1:1.0 in).

Optional composition according to the invention may include monounsaturated fatty acids (MNIK). When these acids in the composition according to the invention it is preferably soda is to reap from about 2 g to 3.5 g MNIC/portion, more preferably from about 2.5 g to 3 g MNIC/a portion of the composition, and from about 3 g to 6 g of polyunsaturated fatty acids per serving, more preferably from about 4.5 g to 5 g of polyunsaturated fatty acids per serving of the composition.

Nutritional supplements according to the invention can also contain a source of carbohydrate (e.g., one or more of the sugar, liquid sucrose, maltodextrin, dried corn syrup, high fructose corn syrup, corn syrup, soluble dietary fiber, trehalose, isomaltulose and fructose). If the composition according to the invention is a mixture of high density of nutrients, it preferably contains slowly or slowly digestible metabolisable sugar, i.e. sugar, the metabolism of which is prolonged in time, and provides slow insulinogenic answer. Consumption of these sugars can improve insulin sensitivity, decrease the concentration of glucose in blood/plasma and accelerate metabolic responses, including improved nitrogen balance and endogenous protein synthesis. Suitable sugars include, for example, isomalt, isomaltulose, trehalose, D-tagatose, tapioca dextrin and sacrament.

Nutritional supplements according to the invention can also contain vitamins (e.g., one or more of vitamins a, C, D, E, K, B, B12, thiamine, Riboflavin, folic acid, Pantothenic acid, Biotin and choline) and minerals (e.g., one or more of Niacin, calcium, iron, manganese, chloride, phosphorus, iodine, magnesium, zinc, copper, sodium, potassium, chromium, molybdenum and selenium).

Peptides derived from milk protein, have been shown to be different bioactive properties, including antihypertensive and antithrombotic properties. Such peptides can serve as carriers for minerals. Peptides derived from casein and whey protein may have additional physiological and/or therapeutic beneficial effect. For example, some peptides released from the casein in the process of digestion can affect gastrointestinal peristalsis, increase the time of passage of food through the gastrointestinal tract and show antidiarrheal effect. This can be especially useful for individuals suffering from weight loss due to disease or treatment of disease. Phosphopeptide casein is capable of preventing the precipitation of calcium phosphate, increasing, thus, the concentration of soluble calcium in the lumen of the small intestine. In addition, bioactive compounds and amino acids whey protein can enhance immune function and maintain health of the gastro-Kish the con tract and can function as antioxidants.

As an additional means for supporting the health of the gastrointestinal tract compositions according to the invention can also contain soluble and/or insoluble dietary fiber. Increased consumption of dietary fiber, as shown, provides many useful benefits, including reducing the time of passage of food; the increase in stool mass; facilitating defecation; strengthen the protective barrier of the intestines (causing prevents the ingress of bacteria into the bloodstream); improved fermentation and production of short-chain fatty acids (CCGC)that serve as the energy source for cells of the intestinal mucosa, and stimulation of immune cells in the gastrointestinal tract.

The introduction of dietary fiber in the composition of the invention may be particularly useful for individuals who need extra calories and protein, and for those who can be treated on reception of drugs" (medication pass program), described in detail below.

Fibers suitable for introduction into the composition of the invention include insoluble fiber and soluble fiber. Insoluble fibers, including cellulose, some hemicelluloses and lignin, are completely insoluble in water and minimal fermentarium in the colon. They show their beneficial effects in the first ocher is d', as the fillers that increase the volume, due to their ability to retain water. Insoluble fiber increases the bulk of stool and reduce the time it passes through the intestinal tract, helping to prevent or relieve constipation. In addition, they can increase the excretion of bile acids. Cellulose and hemicellulose contained in the stem and leafy vegetables and in the outer cover shell of the seed, while the lignin in the stalks and seeds of fruits and vegetables and bran shell grain. Significant amounts of insoluble fiber found in soy, wheat bran and whole grains of other cereals.

Soluble fibers dissolve in water and are amenable to fermentation in the colon. The level of fermentation depends on the degree of solubility and particle size of the fibers. So, with increased solubility and reduced particle size of fiber fermentation them faster and in full. The beneficial effect of soluble fibers is manifested in slow gastric emptying, delayed absorption of some nutrients in the small intestine and in reducing serum cholesterol. Soluble fibers include pectin, gums, some hemicelluloses, shell plantain seed LESNOGO, guar gum, fructo-oligosaccharides (FOS), inulin and galactooligosaccharides (GOS). the addition of a significant amount of soluble fiber found in fruits, vegetables and cereals, such as barley and oats.

During the fermentation process formed by short chain fatty acids (CCGC), and they are assumed to be responsible for some of the beneficial effects attributed to fibers. Acetate, propionate and butyrate contains 83% CCGC formed in the colon. CCGC easily absorbed by the mucous membrane of the intestine and undergo metabolism in the intestine and liver, providing energy, stimulating the absorption of sodium and water in the colon and promoting interstitial growth. Thanks to these properties, CCGC, as expected, reduce the risk and incidence of diarrhoea caused by disease, drugs, and bacterial colonization of the intestine. Butyrate is the preferred fuel for the cells lining the large intestine and is essential for the maintenance of the intestinal mucosa, which is a major barrier, inhibiting the penetration of bacteria into the bloodstream. CCGC also promote a healthy environment in the gut. They inhibit the growth of harmful bacteria and stimulate the growth of beneficial bacteria such as bifidobacteria and lactobacilli. Beneficial bacteria perform several important functions in the gastrointestinal tract, including the maintenance of his health, stimulation of immune responses and suppress the growth of harmful bacteria, especially in the treatment and what tibeticum. Stimulating bacterial growth and fermentation of soluble fiber are mild laxative effect and can be useful for the prevention of constipation or pain relief for constipation.

Some examples of other dietary fibers, which may not necessarily be used in the compositions according to the invention include fiber from bran and seeds; cellulose; chitin; chitosan; hemicellulose; lignin; carbohydrates (e.g., beta-galactooligosaccharide, alpha galactooligosaccharide, fructo-oligosaccharides, frukooligosaharidov, mannooligosaccharide, xylooligosaccharide, sialyl-oligosaccharides, N-glycoprotein-oligosaccharides, O-glycoprotein-oligosaccharide, glycolipid-oligosaccharides, calorigenically, chitosan-oligosaccharides, chitin-oligosaccharides, galactooligosaccharides, glucuronolactone, beta-glucan-oligosaccharides, arabinoxylane, arabinogalactans, xylopyranoside, galactopyranoside, ranoochishchatee); soluble carbohydrates or sugars (e.g., fruit(oz)Ana/inulin, galatanu, fucoidans, aramini, silane, xanthane, beta-glucan, galacturonan, N-glikana, O-glikana, hyaluronic acid, chondroitin, xiloglucanes, arabinogalactane, alginates, carrageenan, galactomannan, arabinoxylane, glycolipid-glikana, glycoprotein-glikana, proteoglycans, spare pleva is s, fructans, galactooligosaccharides legumes, fucoidan, alpha-glucan, laminarin, carrageenan, mannans, galactomannans, agar, natural gum, N-glycoside-linked carbohydrates of glycoproteins, glikana glycolipids obtained by enzymatic carbohydrates (galacto-/gluco-/xylooligosaccharide), bacterial carbohydrates (xanthan gum), oligosaccharides: galacto-/gluco-[alpha-1,2 - and α - 1,3-glucose residues and xylooligosaccharide, cellulose, hemicellulose (aramini, galactanes), pectins, chitina; D-glucose; D-fructose; D-galactose; D-mannose; L-fucose; D-N-acetylglucosamine; D-N-atsetilgalaktozamin; D-xylose; L-rhamnose; D-arabinose; D-allose; D-talose; L-idose; D-ribose; D-galacturonic acid, D-glucurono and D-mannurone acid.

In table 2-4 (see below) provides illustrative examples of the compositions of nutritional supplements according to the invention. Presents compositions have a high calorie - to 2.25; 2.5 and 3.0 cal/ml, although the scope of the invention includes higher and lower amounts of calories. Preferably the amount of calories in the nutritional supplements of the invention is approximately from 2.25 to 3.25 cal/ml

As mentioned above, is nutritional is e additives according to the invention in most cases have a viscosity below 120 SP, preferably below 100 SP, more preferably from about 50 SP 90 SP, most preferably from about 50 SP 75 SP. Having such a viscosity, nutritional supplements according to the invention suitable for oral or enteral administration. If a nutritional Supplement is intended for oral administration, it may be desirable to additionally provide one or more flavoring.

Treatment effects of nutritional deficiencies with the use of high-calorie nutritional supplements

The present invention also includes methods of treating deficiency of nutrients in the individual, providing for the admission of the individual a nutritional Supplement that contains a source of protein, including milk protein isolate and/or canola protein source and fat source carbohydrate and calorie content of about from 2.25 to 3.25 cal/ml Insufficiency of nutrients may be due to disease, disorder or disease state. Receiving nutritional supplements may be oral or enteral route.

Diseases, disorders and painful conditions subject to treatment according to the present invention, include, for example, nervous anorexia, a disease causing exhaustion, such as cancer, acquired immunodeficiency syndrome (AIDS) and sarcopenia (associated with the age of the m loss of muscle mass); chronic diseases, functional disorders, including mental disorders and physical infirmity; deterioration of mental faculties and wounds. High-calorie high-protein nutritional additives, such as additives, provide one alternative embodiment of the present invention is particularly useful for the treatment of muscle loss due to the above and other States.

As noted above, the composition of the invention can include sources of protein, consisting, at least partially, from the branched chain amino acids (ACRC). ICRC, as well as insulin and insulin-like growth factor-1 (IPF-1), inhibit, as has been shown, the protein degradation caused by inducing proteolysis factor (IPF). It is this ability proves the usefulness of therapeutic use of ACRC (either separately or in mixture with each other) together with insulin or IPF-1. In addition, IAP-induced protein breakdown is reduced, as reported, under the action of eicosapentaenoic acid. ACRC able to inhibit the breakdown of protein caused by other factors, in addition to the IAP, which also argues in favor of their therapeutic applications to prevent, among other things, and protein cleavage. Surprisingly, it was found that each of ACRC (leucine, isoleucine and valine) equal the m way effective and the antagonist of protein decomposition. These results are, in particular, interest in the framework of the previously conducted research aimed at studying the ability of specific amino acids (e.g. leucine) to initiate and promote protein synthesis through a mechanism of increased activity of the apparatus of the synthesis. The purpose of these studies was to improve anabolism in skeletal muscle.

The treatment methods of the present invention may include taking medications or other therapeutic agent. In one variation of the embodiment of the nutritional Supplement according to the invention is included in the program use of drugs", in which the individual takes a small amount of nutritional supplements in combination with one or more of the drugs. In a preferred variant embodiment, this joint reception is periodic, providing regular small amounts of nutritional supplements. This method of treatment is particularly useful for individuals who are sensitive to the receipt of large amounts of food or nutritional supplements and exposed as a result of this increased risk of malnutrition or weight loss. Thus, intake of nutritional supplements according to the invention as part of a "program use of drugs" may be in the form of joint reception nutritional supplements and cartonnage means and capable of providing calories and protein to maintain weight and/or additions, protein that promotes the healing of wounds, to prevent a shortage of nutrients associated with inadequate intake of food in the body, to reduce the risk of malnutrition and related complications, improve the appetite, prevent the early onset of satiety and helps the individual to improve the overall intake of nutrients from food. In addition, this trick will help to reduce waste due to failure mode, and to reduce the cost of replacement of malnutrition and weight loss.

The above description of the various aspects of the invention has the purpose of its disclosure and explanation. It is not exhaustive or limit the invention to the precise form of presentation, and it is clear that many possible modifications and variations which may be apparent to the skilled in the art specialist.

1. Nutritional Supplement containing a source of protein, including milk protein isolate or canola protein or milk protein isolate and protein canola; source of fat, a source of carbohydrate and water, and having the calories from 2.25 to 3.25 cal/ml and a viscosity of below 120 SP.

2. A nutritional Supplement according to claim 1, in which the source of the fat comprises at least one of the following: canola oil, corn oil, cottonseed oil, soybean oil, soy lecithin, high oleic p which Solnechnoe oil, sunflower oil, fish oil, medium chain triglycerides, high oleic safflower oil, safflower oil, palm kernel oil, olive oil, borage seed oil (borrajo), black currant oil, evening primrose oil, Flaxseed oil and coconut oil.

3. A nutritional Supplement according to claim 1, in which the source of the carbohydrate comprises at least one of the following: sugar, liquid sucrose, maltodextrin, dried corn syrup, high fructose corn syrup, corn syrup, soluble fiber, trehalose, isomaltulose and fructose.

4. A nutritional Supplement according to claim 1, in which the protein source is milk protein isolate.

5. A nutritional Supplement according to claim 1, in which the protein source includes at least one of the following: total milk protein, milk protein concentrate, soy protein isolate, hydrolyzed whey protein and free amino acid.

6. A nutritional Supplement according to claim 1, in which the source of protein is a protein canola.

7. A nutritional Supplement according to claim 6, in which canola protein includes at least one of the following: the fraction of 2S canola protein, the fraction of 12S canola protein or combinations thereof.

8. A nutritional Supplement according to claim 1, in which the protein source includes at least one of the following: native proteins; free peptides; fractionated proteins and combinations of perejil the frame.

9. A nutritional Supplement according to claim 1, in which the protein source comprises at least one amino acid with branched chain (ACRC).

10. A nutritional Supplement according to claim 9, in which at least one of ACRC includes at least one native ACRC, partially gidralizovanny ICRC, salt ACRC and combinations of the above.

11. A nutritional Supplement according to claim 9, in which at least one of ACRC preferably provides from 5 to 50% of the calories of protein.

12. A nutritional Supplement according to claim 11, in which at least one of ACRC preferably provides from 10 to 40% of the calories of protein.

13. A nutritional Supplement according to claim 11, in which at least one of ACRC preferably provides from 15 to 35% of calories protein.

14. A nutritional Supplement according to claim 11, in which at least one of ACRC preferably provides from 22 to 35% of calories protein.

15. A nutritional Supplement according to claim 1, in which the protein source provides from 10 to 22% of the content of calories in addition.

16. A nutritional Supplement indicated in paragraph 15, in which the source of fat provides from 34 to 55% of the content of calories in addition.

17. A nutritional Supplement indicated in paragraph 15, in which the source of carbohydrate provides from 25 to 55% of the content of calories in addition.

18. A nutritional Supplement according to claim 1, in which the source of the fat comprises at least one n-3 polyunsaturated fatty acid selected from the group consisting of alpha-l is Elenovo acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

19. A nutritional Supplement for p, in which the source of fat includes EPA and DHA in a 2:1 ratio.

20. A nutritional Supplement for p, in which the source of fat includes EPA and DHA in a ratio of 1:2.

21. A nutritional Supplement for p, in which the source of fat includes EPA and DHA in a ratio of 1.5:1.

22. A nutritional Supplement for p, in which the source of fat also includes at least one n-6 polyunsaturated fatty acid.

23. A nutritional Supplement according to article 22, in which the source includes fat n-6 polyunsaturated fatty acids and n-3 polyunsaturated fatty acids in a ratio of from 0.1:1.0 to 1.0 to:0,1.

24. A nutritional Supplement for p, in which the source of fat also includes at least one monounsaturated fatty acid.

25. A nutritional Supplement according to claim 1 also containing at least one vitamin selected from the group consisting of vitamins a, C, D, E, K, B6, B12, thiamin, Riboflavin, folic acid, Pantothenic acid, Biotin and choline.

26. A nutritional Supplement according to claim 1 also containing at least one mineral selected from the group consisting of Niacin, calcium, iron, manganese, chloride, phosphorus, iodine, magnesium, zinc, copper, sodium, potassium, chromium, molybdenum and selenium.

27. A nutritional Supplement according to claim 1 containing also a source of dietary fiber, R is the seer of at least one type of insoluble fiber and soluble fiber.

28. A nutritional Supplement according to item 27, in which at least one type of insoluble fiber and soluble fiber is selected from the group consisting of: cellulose; chitin; chitosan; hemicellulose; lignin; beta-galactooligosaccharides, alpha galactooligosaccharides, fructo-oligosaccharides, focalisation, mannooligosaccharides, xylooligosaccharides, sialyl-oligosaccharides, N-glycoprotein-oligosaccharides, O-glycoprotein-oligosaccharide, glycolipid-oligosaccharides, caloryguard, chitosan-oligosaccharides, chitin-oligosaccharides, galactooligosaccharides, glukuronkongugatov, beta-glucan-oligosaccharides, arabinoxylanes, arabinogalactans, xylopyranoside, galactopyranoside, runoilijaneidon; fruits(oz)ANOVA/inuline, galatanu, fucoidans, arabino, zilanov, xantana, beta-glucans, galacturonans, N-glycans, O-glycans, hyaluronic acid, chondroitin, xyloglucans, arabinogalactans, alginates, karraginanom, galactomannans, arabinoxylanes, glycolipid-glycans of glycoprotein-glycans, proteoglycans, spare carbohydrates, fructans, galactooligosaccharides legumes, fucoidan, alpha-glucan, laminarin, carrageenan, mannans, galactomannans, agar, natural gums, N-glycoside-linked carbohydrates of glycoproteins, glycans Glyco is Obidov, galacto-/gluco-/xylooligosaccharides, bacterial carbohydrates, xanthan gum, oligosaccharides: galacto-/gluco-[alpha-1,2 - and α-1,3-glucose residues] and xylooligosaccharides, pectins, chetinov; D-glucose; D-fructose; D-galactose; D-mannose; L-fucose: D-N-acetylglucosamine; D-N-atsetilgalaktozamin; D-xylose; L-ramnose; D-arabinose; D-allose; D-talose; L-idose; D-ribose; D-galacturonic acid; D-glucuronic and D-mannurone acid.

29. A nutritional Supplement according to claim 1, in which the source of the carbohydrate comprises at least one of the following: isomalt, isomaltulose, trehalose, D-tagatose, tapioca dextrin and sacrament.

30. A nutritional Supplement according to claim 1, also containing flavoring additive.

31. A nutritional Supplement according to claim 1 having a viscosity less than 100 CP.

32. A nutritional Supplement according to claim 1, having a viscosity of from 50 to 120 SP.

33. A nutritional Supplement according to claim 1, having a viscosity of from 50 to 90 SP.

34. Method for the production of nutritional supplements that contain a source of protein, including milk protein isolate or canola protein or milk protein isolate and protein canola; source of fat, a source of carbohydrate and water content of calories from 2.25 to 3.25 cal/ml and a viscosity of below 120 JV, where the method includes the following stages:
(1) preparation of a mixture of water and source of protein, including milk protein isolate, and, if necessary, the source of fat and/or history is nick carbohydrate;
(2) the exposure of the mixture to treatment with direct injection of steam (PIP);
(3) add a source of fat and/or source of carbon to the mixture, if it was not done at the stage (1);
(4) the homogenization of the mixture.

35. The method according to clause 34, in which the mixture further includes at least one of the following: antifoam, citrate, vitamin, mineral and flavoring additive.

36. The method according to clause 34, in which water has a temperature of from 48,9 to 87.8°C.

37. The method according to p, in which water has a temperature of 51.7 to 79.4°C.

38. The method according to clause 37, in which water has a temperature of from 54,4 to 65.6°C.

39. The method according to § 38, in which water has a temperature of from 57,2 to 62.8°C.

40. The method according to clause 34, in which the PIP processing includes heating the mixture to UAH 121.1°C for 45 S.

41. The method according to p, in which PIP-processing further includes instant cooling of the mixture in the vacuum chamber to 71.1°C.

42. The method according to clause 34, which also includes the stage of adding to the mixture of at least one of the following: citrate, vitamin, mineral and flavor additives.

43. The method according to clause 34, which also includes the stage of cooling the mixture to a temperature below 7.2°C.

44. The method according to clause 34, which also includes the stage of exposure to a mixture of secondary PIP-processing, which includes heating the mixture to a temperature above 137,8°C.

45. A nutritional Supplement according to any one of claims 1 to 33, used in the treatment of deficit is and nutrients from the individual.

46. A nutritional Supplement according to item 45, additionally comprising at least one medicine.

47. A nutritional Supplement according to § 45, in the form acceptable for oral administration.

48. A nutritional Supplement according to § 45, in the form acceptable for enteral administration.

49. A nutritional Supplement according to item 45, where the individual suffers from at least one of the following: anorexia nervosa, a disease that causes exhaustion, such as cancer, acquired immunodeficiency syndrome (AIDS) and sarcopenia; chronic disease; functional disorders, including mental disorders and physical infirmity; deterioration of mental capacity or has a wound.

50. The use of a nutritional Supplement according to any one of claims 1 to 33 in combination with one or more of the drugs for the treatment of deficiencies in the individual.



 

Same patents:

FIELD: food industry.

SUBSTANCE: invention is related to alimentary therapy. Proposed is a method providing for a cancer patient long-term alimentation and envisaging long-term administration of a nutritional product to the patient through a probe, the product containing a protein source providing for 14-25% of the product energy value and composed of whey (50% of energy value), glutamine (0.5% - 10% of energy value), leucine (0.8% - 3.5% of energy value), a carbohydrate source (20-55% of the product energy value) and a lipid source ( 25-40% of the product energy value). Optionally, the method envisages first administration of the above composition to a tumour cancer patient (through a probe) and then, upon normal metabolic status recovery - administration of a second composition for long-term alimentation that differs from the first composition in terms of formulation. Optionally, the method providing for a cancer patient long-term alimentation envisages administration of glutamine together with the above nutritional composition at least a week prior to commencement of the cancer therapy course.

EFFECT: invention enables to ensure well-balanced and efficient long-term through-probe alimentation of a cancer patient.

36 cl, 4 ex

Antioxidant complex // 2419362

FIELD: food industry.

SUBSTANCE: invention is related to food industry, in particular - to production of specialised products based on natural raw materials that may be used for alimentation of sportsmen as well as persons leading an active lifestyle. The antioxidant complex contains dihydroquercetin, L-carnozine, zinc citrate, selenopyran and vitamins A, C, E at a certain ratio. The invention enables reliable protection against multiple effects of oxidation and free radical impact.

EFFECT: maximally efficient dosage of the active components and absolutely accurately selected proportion of antioxidants in the formulated complex composition enable manifold intensification of the organism protective function and a significant cascade antioxidant action.

4 cl

FIELD: food industry.

SUBSTANCE: protein system contains a source of moisture, a combination of intact proteins, casein and partly hydrolysed milk protein and partly hydrolysed bean protein in a total quantity efficient for reduction of the required mixing time and/or shear force and for reduction of hardness development in the course of processing and storage of food products with extended storage life. Reduced staleness is ensured without bitterness imparted to the food product in case of usage of the protein mixture providing for a unique balance of partly hydrolysed and intact proteins and casein. Also considered are methods for manufacture of food products with protein mixtures.

EFFECT: invention enables production of protein systems for food products having enhanced storage life that preserve soft and moist texture in the course of time.

24 cl, 5 dwg, 5 tbl, 1 ex

FIELD: food industry.

SUBSTANCE: invention relates to a nutritional composition for babies. The composition includes a lipidic component and a digestible carbohydrate component. The lipidic component includes linolic acid (LA) and alpha-linolic acid (ALA), the LA/ALA weight ratio being from 2 to 7, the amount of LA being less than 14.5 wt %. of the total weight of fatty acids, the amount of ALA being from 1 wt % to 10 wt % of the total weight of fatty acids. The composition additionally includes at least one component chosen from the group consisting of: from 0.5 to 20 wt % of phospholipids of the total fat weight; from 0.035 to 1 wt % of choline of the total weight of the dry composition and from 0.001 to 0.1 wt % of uridine in the form of nucleotide, nucleoside and/or base of the total weight of the dry composition.

EFFECT: invention allows to prevent adiposity occurrence at an age of over 36 months by way of feeding the said nutritional composition to the baby at an age of under 36 months.

16 cl, 5 tbl, 4 ex

FIELD: food industry.

SUBSTANCE: invention refers to chemistry and food industry. Proposed is a mineral nutrient salt stabilised with amino acids and/or an ammonium salt. The salt is produced with organic acids anions or inorganic anions and metal cations bound to the amino acids and/or the ammonium salt. The metal cations are bound via ionic linkage to the anions and via covalent semi-polar linkage - to the amino acids amino group and/or the ammonium salt. The salt is represented by its general formula: {[Ac]n-·Men+ ← n [amino acid and/or ammonium salt]}·x H2O, where ← is covalent semi-polar linkage. Additionally proposed are a product and a food supplement containing such salt and a method for its production.

EFFECT: invention enables production of salts possessing improved taste and better solubility in water which renders them more biologically available.

16 cl, 2 dwg, 2 ex

FIELD: food industry.

SUBSTANCE: invention relates to food industry, namely, to production of biologically active additives based on water-soluble proteins contained in salmon fishes liver. The method involves initial raw material selection, extraction, solid fraction separation, target product decontamination and drying. The initial raw material is represented by salmon fishes liver (fresh, frozen or dried). Extraction is performed with distilled water, the raw material to extractive agent ratio being 1:5 -1:30 which is followed by the suspension alkalisation till pH is 8-9 and infusion at room temperature during 2-4 h accompanied by stirring. Then one proceeds with the target product decontamination by way of the solid fraction treatment with a 0.3% solution of chitosan in a 3% solution of an organic food acid, pH being 2.5-3.0 in a 1:20 ratio during 1 h accompanied by stirring with subsequent incubation of the mixture during 2-3 h. One performs double separation into the solid and the liquid fractions with subsequent depletion of the liquid fractions.

EFFECT: invention allows to produce a water-soluble polypeptide complex of salmon fishes liver which is characterised by a balanced amino acid composition, an enhanced taurine content and a high antioxidant activity.

2 cl, 3 dwg, 1 tbl, 4 ex

FIELD: food industry.

SUBSTANCE: invention is related to phytotherapy. The biologically active supplement possessing antidepressant effect contains L-tryptophan, linseed-oil and vegetal components. The vegetal components are represented by oil extract of mother-of-thyme herb, common origanum herb, St.-John's wort herb, sandy everlasting blossom, common valerian root with rhizomes and elecampane root with rhizomes taken in a ratio of 0.8-1.2:0.8-1.2:0.8-1.2:0.8-1.2:0.8-1.2:0.8-1.2 accordingly and a dried water extract produced by way of expression of the same components after oil extraction. The biologically active supplement production method envisages mixture of the above components. The oil extract is produced by extracting the vegetal raw material with vegetable oil at a temperature of 50-70°C during 5-10 h with subsequent separation of the raw material. The water extract is produced by extracting the raw material, expressed after oil extraction, with water at a temperature of 50-70°C during 5-10 h with subsequent filtrate filtering and drying to produce the dry solid.

EFFECT: invention enables production of a supplement that is efficient in therapy of different forms of stress including sleep disturbance with patients of different age groups, aggressiveness, instability of temper, state of anxiety, has a positive effect on normalisation of the brain electrical activity indices and basic brain blood circulation indices and possessing antioxidant action.

9 cl, 4 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: there is offered the application of protein and/or peptide fractions containing at least 10.8 wt % of aspartate (or containing 12.0-40 wt % of aspartate per total protein fraction) for preparing a nutritional composition for plasma glucose level control and/or digestive insulin sensitivity enhancement in mammals, containing glucose (versions) and applicable nutritional compositions. It is shown that high amounts of aspartate, especially with the relative absence of glutamate equivalents promote glucose absorption in peripheral cells and improve a hepatic reaction on dietary glucose uptake. The nutritional composition contains protein, preferentially recovered from soya or milk and additionally enriched with aspartate in mass ratio of aspartate equivalents and glutamate equivalents (asp:glu) within 0.41:1 to 5:1.

EFFECT: enabled favourable effect on blood glucose levels in a patient suffering hyperglycemia and/or insulin resistance.

27 cl, 2 dwg, 2 tbl, 7 ex

FIELD: food industry.

SUBSTANCE: invention relates to food industry, in particular - to nutritional sialic acid containing formulas for babies and infants and such formulas manufacture methods. The infant formula contains fats, carbohydrates, vitamins, minerals and albumin. The said albumin contains caseinoglycomacropeptide in an amount sufficient to increase the total content of sialic acid from approximately 250 mg to approximately 1500 mg per litre of infant formula. Sialic acid content in caseinoglycomacropeptide is over 60 mg per g of caseinoglycomacropeptide. The infant formula manufacture method involves mixture of the sources of albumin, carbohydrates, vitamins, minerals and fats in amounts sufficient for production of a full-value infant formula.

EFFECT: invention implementation enables minimisation of distortion of the amino acid profile of the albumin contained in the infant formula combined with its sialic acid content increase.

7 cl, 12 tbl, 9 ex

FIELD: food industry.

SUBSTANCE: invention refers to pharmacology. Method for improvement of microelements absorption from gastrointestinal track in a subject, includes injection of agent to a subject (a person or animal), including alpha-ketoglutarate or its salt, in which microelement is selected from a group made of iron, zinc, manganese, strontium, copper or calcium. Besides when manganese is the microelement, alpha-ketoglutarate or its salt may be introduced as component of peroral contrast substance, where manganese absorption by gall and liver assists in diagnostics of tumors in tissues of gastrointestinal track.

EFFECT: development of new method for diagnostics of tumors in tissues of gastrointestinal track.

10 cl, 4 tbl, 3 ex, 4 dwg

FIELD: food industry.

SUBSTANCE: invention is related to alimentary therapy. Proposed is a method providing for a cancer patient long-term alimentation and envisaging long-term administration of a nutritional product to the patient through a probe, the product containing a protein source providing for 14-25% of the product energy value and composed of whey (50% of energy value), glutamine (0.5% - 10% of energy value), leucine (0.8% - 3.5% of energy value), a carbohydrate source (20-55% of the product energy value) and a lipid source ( 25-40% of the product energy value). Optionally, the method envisages first administration of the above composition to a tumour cancer patient (through a probe) and then, upon normal metabolic status recovery - administration of a second composition for long-term alimentation that differs from the first composition in terms of formulation. Optionally, the method providing for a cancer patient long-term alimentation envisages administration of glutamine together with the above nutritional composition at least a week prior to commencement of the cancer therapy course.

EFFECT: invention enables to ensure well-balanced and efficient long-term through-probe alimentation of a cancer patient.

36 cl, 4 ex

FIELD: food industry.

SUBSTANCE: invention relates to a nutritional composition for babies. The composition includes a lipidic component and a digestible carbohydrate component. The lipidic component includes linolic acid (LA) and alpha-linolic acid (ALA), the LA/ALA weight ratio being from 2 to 7, the amount of LA being less than 14.5 wt %. of the total weight of fatty acids, the amount of ALA being from 1 wt % to 10 wt % of the total weight of fatty acids. The composition additionally includes at least one component chosen from the group consisting of: from 0.5 to 20 wt % of phospholipids of the total fat weight; from 0.035 to 1 wt % of choline of the total weight of the dry composition and from 0.001 to 0.1 wt % of uridine in the form of nucleotide, nucleoside and/or base of the total weight of the dry composition.

EFFECT: invention allows to prevent adiposity occurrence at an age of over 36 months by way of feeding the said nutritional composition to the baby at an age of under 36 months.

16 cl, 5 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely, to psychiatry, and deals with treatment of depression, resistant to psychopharmacotherapy. For this purpose realised is fasting-diet therapy. Duration of fasting period is determined by dynamics of ketone level in patient's urine. Ketone level is determined daily, diagram of level dynamics is built, development of second peak is an indicator for finishing fasting period and transition to restoring period of fasting-diet therapy.

EFFECT: method ensures increase of treatment efficiency in absence of side effects due to introduction of objective criterion of fasting period end.

1 ex, 1 tbl, 2 dwg

FIELD: food industry.

SUBSTANCE: invention relates to a biscuit with high fibre content produced by rotational moulding. The biscuit essentially contains a homogeneous mixture of wheat flour, at least one sugar, at least one shortening agent or fat, inuline and resistant starch. The total content of inuline and resistant starch is at least 10% (weight) of the total weight of wheat flour, inuline quantity 10% - 90% (weight) of the total content of inuline and resistant starch; fibre content in the biscuit is at least 7% (weight) of the total weight of the rotationally moulded biscuit. The biscuit may be presented in the form of matching piece-goods shaped as faces and bodies thus providing for a form with a game parametre combined with rendering the product more wholesome for children.

EFFECT: invention allows to produce a softer biscuit having, however, a crispy texture and reduced caloric content; the biscuit has a form with clearly defined, clear-cut contours, a sharp press print and impression, a homogeneous colour and texture.

20 cl, 2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed are: nutrient composition, which contains 0.5-20 wt % of phospholipids, 0.1-20 wt % of sphingolipids and 0.005-10 wt % of cholesterol from total lipid content, protein and carbohydrates, intended for child form 36 months for prevention of obesity and/or diabetes, its application for treatment of type two diabetes and/or nutrient regulation of type two diabetes, as well as its application for prevention of disorder development, when age of mentioned child exceeds 36 months, said disorder is selected from group, which consists of type two diabetes, hyperglycemia at starvation, insulin immunity, visceral obesity, hyper-insulinemia, hypertension, cardiovascular diseases, cerebral vessel diseases, arthrosclerosis, dislipidemia, hyperuricemia, fatty liver dystrophy and sleep apnea.

EFFECT: reduction of insulin level in blood plasma after introduction of claimed composition against introduction of standard composition for children nutrition, which indicates increased sensitivity to insulin, which favours obesity prevention in more mature age.

10 cl, 2 tbl, 3 ex

FIELD: food industry.

SUBSTANCE: invention relates to food industry, and namely to its confectionary branch. First isomalt or lactitol are mixed with dry milk in boiling device. Dissolution of produced mixture in water, taken in amount of 35-40 wt % from mixture weight, with gradual heating of produced solution to temperature of 110-115°C and continuous mixing, adding treacle heated up to 65-75°C, melted fat component and emulsifier. Emulsification of produced mixture is carried out for 3-5 minutes. It is boiled to the temperature of 130-132°C until content of dry substances is 92-94 %. Then mass is cooled down to temperature of 85-90°C, flavour is added into mass, it is moulded, and items are wrapped in moulding-wrapping device. Components are used in appropriate ratio.

EFFECT: invention provides for expansion of assortment of toffee of preventive purpose with dietary and diabetic properties by reduction of content of hydrocarbons, reduction of calorie content and improvement of quality.

4 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to restorative medicine and rehabilitation, and can be used for prevention of renal insufficiency in complex correction of an obesity patient state. That is ensured by reducing dietary treatment (RDT) under Cal-Calif intoxication index (II) with underlying music therapy, psychocorrection, dynamic motor conditions. At the 1st stage, 1-2 days hypocaloric vegetable-cereal diet of caloric content 1800-2200 kcal/day is prescribed. Then, at the 2nd stage, if observing the II increasing more than 3.9 standard units, the vegetable-cereal diet is kept for 15-19 days in the patient and combined with daily depletion. If the II is decreasing to 3.9 standards units and lower, the patient is moved either to a starvation diet, or to a diet of daily calorage limited by 1000-1500 kcal. After the 2nd stage completed, daily caloric content of food is gradually increased to 2200 kcal for 15 days.

EFFECT: method provides more effective RDT and allows controlling endotoxicosis degree and functional kidney load that allows reducing a percentage of renal complications representing transient renal insufficiency.

3 cl, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to hematology and cardiology. Method includes administration to patients of complex from hypocaloric diet, dosed static and dynamic physical activity, including morning hygienic gymnastics, preventive medical gymnastics, divided physical exercise throughout the day, daily swimming for not less than 30 min per day in the middle of the day, intake of lisinopril in dose 10 mg 1 time per day in the morning and simvastatin 20 mg 1 time per day in the morning during 2 months. Combined application of all components makes it possible to reduce SEA in patients with AH with AO and D, reducing it to the level close to such for healthy people, during 2 months of treatment.

EFFECT: reduction of spontaneous erythrocyte aggregation (SEA) in case of arterial hypertension (AH) with abdominal obesity (AO) and dyslipidemia (D).

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of preventive medicine and can be used as additional means for correction of tripsin-inhibitory activity. Method of regulating tripsin-inhibitory activity of blood serum in organism consists in daily intake for 2 months of soya pastry with 30% content of soya protein isolate in amount 100 g per day. Protein contains 39000 IU of active tripsin inhibitor.

EFFECT: invention makes it possible to regulate tripsin-inhibitory activity in organism in order to prevent pathologic processes accompanied by inflammation.

2 tbl, 1 ex

FIELD: food industry.

SUBSTANCE: invention relates to food industry. Girasol is washed, peeled and chopped. Chopped girasol is separated into fibre and juice by way of centrifugation or pressing. Fibre is dried in a drying chamber till moisture content is 12-14% at a 110-120°C temperature and milled to produce powder with 10-20 mcm particle size. Juice is filtered. Girasol juice and powder, starch-and-maize molasses, starch, a fruit essence, citric acid are mixed and the mixture is boiled out at a 100°C temperature during 55-60 min. The syrup is chilled to 40°C. At the same time, egg whites are whipped to produce fluffy foam wherein chilled syrup is trickled. Then product is whipped to produce a fluffy mass which is then rolled into a 20-25 mm thick sheet on a flour substrate. The sheet is dried during 3-4 hours at a 25-30°C temperature and cut into 20×35 mm sized pieces. The confectionary product contains girasol juice and powder with 10-20 mcm particle size, starch-and-maize molasses, starch, citric acid, a fruit essence, flour used for shaping and egg yolks. All the components are used at a specified ratio.

EFFECT: invention enables enhancement of quality and nutritional and biological value of the product and results in assortment extension.

2 cl, 4 tbl, 4 ex

FIELD: food-processing industry, in particular, production of gerodietary food.

SUBSTANCE: method involves preparing and mixing cabbage, tomato, onion, carrot and edible salt; packing resultant mixture; while mixing said components, additionally introducing fermentolysate of fish processing wastes and acidic hydrolisate of fish processing wastes, soya texturizer, flour of bean, sorghum groats, CO2-extract of dill and celery, rape-seed oil, and preparation produced from Mortierella lignicola microorganism biomass by sequential extraction with the use of non-polar extractant in above-critical state, water, alkaline, water, acid, water, alkaline, and water, with following joining of first extract with solid residue. Components are used in dried state and at predetermined ratio.

EFFECT: wider range of gerodietary products.

Up!